Similar articles for PMID: 11208851

Year	Number of Results
1983	1
1987	4
1988	5
1989	5
1990	5
1991	2
1992	7
1993	5
1994	5
1995	4
1996	3
1997	4
1998	4
1999	4
2000	1
2001	10
2002	8
2003	9
2004	6
2005	12
2006	5
2007	1
2008	1
2009	5
2010	3
2011	3
2013	3
2014	1
2015	3
2016	4
2017	5
2018	2
2019	4
2020	4
2021	6
2022	2
2023	2
2024	0

1

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.

Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J. Major P, et al. J Clin Oncol. 2001 Jan 15;19(2):558-67. doi: 10.1200/JCO.2001.19.2.558. J Clin Oncol. 2001. PMID: 11208851

2

Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.

Major PP, Coleman RE. Major PP, et al. Semin Oncol. 2001 Apr;28(2 Suppl 6):17-24. doi: 10.1016/s0093-7754(01)90261-1. Semin Oncol. 2001. PMID: 11346861 Review.

3

The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.

Major P. Major P. Oncologist. 2002;7(6):481-91. doi: 10.1634/theoncologist.7-6-481. Oncologist. 2002. PMID: 12490736 Free article. Review.

4

A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.

Kawada K, Minami H, Okabe K, Watanabe T, Inoue K, Sawamura M, Yagi Y, Sasaki T, Takashima S. Kawada K, et al. Jpn J Clin Oncol. 2005 Jan;35(1):28-33. doi: 10.1093/jjco/hyi005. Jpn J Clin Oncol. 2005. PMID: 15681601 Clinical Trial.

5

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.

Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ. Rosen LS, et al. Cancer. 2003 Oct 15;98(8):1735-44. doi: 10.1002/cncr.11701. Cancer. 2003. PMID: 14534891 Free article. Clinical Trial.

6

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.

Pecherstorfer M, Steinhauer EU, Rizzoli R, Wetterwald M, Bergström B. Pecherstorfer M, et al. Support Care Cancer. 2003 Aug;11(8):539-47. doi: 10.1007/s00520-003-0477-1. Epub 2003 Jun 3. Support Care Cancer. 2003. PMID: 12783289 Clinical Trial.

7

Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).

Kraj M, Pogłód R, Maj S, Pawlikowski J, Sokołowska U, Szczepanik J. Kraj M, et al. Acta Pol Pharm. 2002 Nov-Dec;59(6):478-82. Acta Pol Pharm. 2002. PMID: 12669777 Free article. Clinical Trial.

8

Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.

Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, Henderson IC, Mallette LE. Nussbaum SR, et al. Am J Med. 1993 Sep;95(3):297-304. doi: 10.1016/0002-9343(93)90282-t. Am J Med. 1993. PMID: 8368227 Clinical Trial.

9

Zoledronic acid: a new parenteral bisphosphonate.

Li EC, Davis LE. Li EC, et al. Clin Ther. 2003 Nov;25(11):2669-708. doi: 10.1016/s0149-2918(03)80327-2. Clin Ther. 2003. PMID: 14693298 Review.

10

Treatment of hypercalcemia of malignancy with bisphosphonates.

Berenson JR. Berenson JR. Semin Oncol. 2002 Dec;29(6 Suppl 21):12-8. doi: 10.1053/sonc.2002.37417. Semin Oncol. 2002. PMID: 12584690 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

151 results

Results by year